KIRIN Central Research Institute, Kirin Holdings Company, Ltd., Kanagawa, Japan.
Department of Psychiatry, Juntendo University Faculty of Medicine, Tokyo, Japan.
J Alzheimers Dis. 2020;76(1):387-398. doi: 10.3233/JAD-200229.
Prevention of age-related cognitive decline and depression is becoming urgent because of rapid growing aging populations. Effects of vagal nerve activation on brain function by food ingredients are inadequately investigated; matured hop bitter acid (MHBA) administration reportedly improves cognitive function and depression via vagal nerve activation in model mice.
We investigated the effects of MHBA supplementation on cognitive function and mood state in healthy older adults with perceived subjective cognitive decline.
Using a randomized double-blind placebo-controlled trial design, 100 subjects (aged 45-69 years) were randomly assigned into placebo (n = 50) and MHBA (n = 50) groups, and received placebo or MHBA capsules daily for 12 weeks.
Symbol Digit Modalities Test (SDMT) score assessing divided attention at week 12 was significantly higher (p = 0.045) and β-endorphin at week 12 was significantly lower (p = 0.043) in the subjects receiving MHBA. Transthyretin in serum, a putative mild cognitive impairment marker, was significantly higher at week 12 in the MHBA group than in the placebo group (p = 0.048). Subgroup analysis classified by the subjective cognitive decline questionnaire revealed that in addition to improved SDMT scores, memory retrieval assessed using the standard verbal paired-associate learning tests and the Ray Verbal Learning Test at week 12 had significantly improved in the subgroup with perceived subjective cognitive decline and without requirement for medical assistance in the MHBA group compared with that in the placebo group.
This study suggested that MHBA intake improves cognitive function, attention, and mood state in older adults.
由于人口老龄化的迅速增长,预防与年龄相关的认知能力下降和抑郁变得尤为紧迫。食物成分对迷走神经激活的影响尚未得到充分研究;据报道,成熟啤酒花酸(MHBA)通过迷走神经激活可改善模型小鼠的认知功能和抑郁。
我们调查了 MHBA 补充对有感知主观认知能力下降的健康老年人认知功能和情绪状态的影响。
采用随机双盲安慰剂对照试验设计,将 100 名(年龄 45-69 岁)受试者随机分为安慰剂(n = 50)和 MHBA(n = 50)组,每天分别接受安慰剂或 MHBA 胶囊治疗 12 周。
12 周时符号数字模态测试(SDMT)评分评估注意力分散显著更高(p = 0.045),β-内啡肽显著更低(p = 0.043),提示 MHBA 组受试者接受 MHBA 治疗。血清转甲状腺素,一种潜在的轻度认知障碍标志物,12 周时 MHBA 组显著高于安慰剂组(p = 0.048)。亚组分析根据主观认知能力下降问卷分类,除了 SDMT 评分的改善外,12 周时使用标准言语配对联想学习测试和 Ray 言语学习测试评估的记忆检索在 MHBA 组的有感知主观认知能力下降且无需医疗辅助的亚组中也显著改善,而安慰剂组无改善。
本研究表明,MHBA 摄入可改善老年人的认知功能、注意力和情绪状态。